Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | TDP2 | O95551 | 3/20 | 1.00 |
| ▸ | NGF | P01138 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | USP2 | O75604 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | HAT1 | O14929 | 4/20 | 0.44 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.44 |
| ▸ | CASP7 | P55210 | 3/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15683182 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTRECQLTDP2 | |
| Lumiflavin SCHEMBL29516802 | 0.86 | MEN1 (0.76) | MEN1KMT2AMAPTRECQLTDP2 | |
| Lumiflavin SCHEMBL193713 | 0.86 | MEN1 (0.76) | MEN1KMT2AMAPTRECQLTDP2 | |
| Lumiflavin SCHEMBL6365933 | 0.85 | MEN1 (0.74) | MEN1KMT2AMAPTRECQLTDP2 | |
| Lumiflavin SCHEMBL6373617 | 0.84 | MEN1 (0.72) | MEN1KMT2AMAPTRECQLTDP2 | |
| SCHEMBL9022677 | 0.82 | MEN1 (0.69) | MEN1KMT2AMAPTRECQLTDP2 | |
| SCHEMBL864918 | 0.82 | MEN1 (0.69) | MEN1KMT2AMAPTRECQLTDP2 | |
| SCHEMBL22458758 | 0.81 | MEN1 (0.68) | MEN1KMT2AMAPTRECQLTDP2 | |
| SCHEMBL10285873 | 0.80 | MEN1 (0.66) | MEN1KMT2AMAPTRECQLTDP2 | |
| SCHEMBL16557144 | 0.80 | MEN1 (0.66) | MEN1KMT2AMAPTRECQLTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4294377-A1 | MSI2 AS A THERAPEUTIC TARGET FOR THE TREATMENT OF MYOTONIC DYSTROPHY | Universitat de València (ES) | 2023-12-27 | — | — | EP | claimed |
| WO-2022175478-A1 | MSI2 AS A THERAPEUTIC TARGET FOR THE TREATMENT OF MYOTONIC DYSTROPHY | UNIVERSITAT DE VALÈNCIA (ES) | 2022-08-25 | — | — | WO | claimed |
| CN-113164483-B | Pharmaceutical composition for preventing or treating cancer containing PLK1 inhibitor as active ingredient | 国立癌症中心 | 2024-09-24 | — | — | CN | disclosed |
| EP-4294377-A1 | MSI2 AS A THERAPEUTIC TARGET FOR THE TREATMENT OF MYOTONIC DYSTROPHY | Universitat de València (ES) | 2023-12-27 | — | — | EP | disclosed |
| WO-2022175478-A1 | MSI2 AS A THERAPEUTIC TARGET FOR THE TREATMENT OF MYOTONIC DYSTROPHY | UNIVERSITAT DE VALÈNCIA (ES) | 2022-08-25 | — | — | WO | disclosed |
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | NATIONAL CANCER CENTER (KR) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033405-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING PLK1 INHIBITOR AS ACTIVE INGREDIENT | PLK1, PLK2, PLK4 | MEN1 2253/4885KMT2A 1439/4885MAPT 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.